Expression of naloxone-resistant β-endorphin binding sites on A20 cells

effects of concanavalin A and dexamethasone

Mahmoud Shaker, Nahid A. Shahabi, Burt Sharp

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

β-Endorphin affects mononuclear cell proliferation, cytokine production and calcium uptake in a naloxone-resistant manner. The presence of naloxone-insensitive binding sites for β-endorphin have been demonstrated on murine EL4-thymoma cells, transformed human mononuclear cells and normal murine splenocytes. Since murine splenic B cells have been shown to express naloxone-resistant receptors for β-endorphin in response to the mitogen, concanavalin A (Con A), the A20 B-cell lymphoma line was used to further study regulation of this site by Con A and dexamethasone. Analyses showed two sites: a high-affinity site, Kd1 = (8.7 ± 2.3) × 10-11 M and binding capacity (Bmax1 ) of (2.6 ± 2.0) × 103 receptors/cell; and a low-affinity site, Kd2 = (2.2 ± 0.8) × 10-8 M with Bmax2 of (1.5 ± 0.8) × 105 receptors/cell. Competition studies showed that N-acetyl-β-endorphin was approx. 5-fold and β-endorphin6-31 10-fold less potent than β-endorphin1-31. Neither β-endorphin1-27 nor naloxone, morphine or other opioid receptor agonists displaced [125I]β-endorphin. Con A (20 μg/ml) significantly increased the Bmax (3.5-fold; expressed per cell) and resulted in a loss of the higher-affinity site. However, the increased Bmax occurred in proportion to the Con-A-induced increase in protein/cell. Dexamethasone (Dex) also increased Bmax, primarily by increasing (2-3-fold) the number of lower affinity sites. In contrast to Con A, two binding sites persisted after treatment with Dex, which exerted a minimal effect on protein/cell. Therefore, binding/cell and binding/protein/cell were both significantly enhanced by Dex. The combined effects of Dex and Con A on binding failed to show additivity or synergy. When binding was analyzed per protein/cell, the effect of Con A appeared to dominate; the Dex-enhanced binding/protein/cell was no longer evident in the presence of Dex plus Con A. Thus, Dex and Con A may enhance binding by independent mechanisms.

Original languageEnglish (US)
Pages (from-to)183-192
Number of pages10
JournalImmunopharmacology
Volume28
Issue number3
DOIs
StatePublished - Jan 1 1994

Fingerprint

Endorphins
Naloxone
Concanavalin A
Dexamethasone
Binding Sites
Concanavalin A Receptors
Proteins
Thymoma
Opioid Receptors
B-Cell Lymphoma
Mitogens
Morphine
Carrier Proteins
B-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Expression of naloxone-resistant β-endorphin binding sites on A20 cells : effects of concanavalin A and dexamethasone. / Shaker, Mahmoud; Shahabi, Nahid A.; Sharp, Burt.

In: Immunopharmacology, Vol. 28, No. 3, 01.01.1994, p. 183-192.

Research output: Contribution to journalArticle

@article{70c9a9c57a0b4737b537bb379be64c23,
title = "Expression of naloxone-resistant β-endorphin binding sites on A20 cells: effects of concanavalin A and dexamethasone",
abstract = "β-Endorphin affects mononuclear cell proliferation, cytokine production and calcium uptake in a naloxone-resistant manner. The presence of naloxone-insensitive binding sites for β-endorphin have been demonstrated on murine EL4-thymoma cells, transformed human mononuclear cells and normal murine splenocytes. Since murine splenic B cells have been shown to express naloxone-resistant receptors for β-endorphin in response to the mitogen, concanavalin A (Con A), the A20 B-cell lymphoma line was used to further study regulation of this site by Con A and dexamethasone. Analyses showed two sites: a high-affinity site, Kd1 = (8.7 ± 2.3) × 10-11 M and binding capacity (Bmax1 ) of (2.6 ± 2.0) × 103 receptors/cell; and a low-affinity site, Kd2 = (2.2 ± 0.8) × 10-8 M with Bmax2 of (1.5 ± 0.8) × 105 receptors/cell. Competition studies showed that N-acetyl-β-endorphin was approx. 5-fold and β-endorphin6-31 10-fold less potent than β-endorphin1-31. Neither β-endorphin1-27 nor naloxone, morphine or other opioid receptor agonists displaced [125I]β-endorphin. Con A (20 μg/ml) significantly increased the Bmax (3.5-fold; expressed per cell) and resulted in a loss of the higher-affinity site. However, the increased Bmax occurred in proportion to the Con-A-induced increase in protein/cell. Dexamethasone (Dex) also increased Bmax, primarily by increasing (2-3-fold) the number of lower affinity sites. In contrast to Con A, two binding sites persisted after treatment with Dex, which exerted a minimal effect on protein/cell. Therefore, binding/cell and binding/protein/cell were both significantly enhanced by Dex. The combined effects of Dex and Con A on binding failed to show additivity or synergy. When binding was analyzed per protein/cell, the effect of Con A appeared to dominate; the Dex-enhanced binding/protein/cell was no longer evident in the presence of Dex plus Con A. Thus, Dex and Con A may enhance binding by independent mechanisms.",
author = "Mahmoud Shaker and Shahabi, {Nahid A.} and Burt Sharp",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0162-3109(94)90053-1",
language = "English (US)",
volume = "28",
pages = "183--192",
journal = "Immunopharmacology",
issn = "0162-3109",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Expression of naloxone-resistant β-endorphin binding sites on A20 cells

T2 - effects of concanavalin A and dexamethasone

AU - Shaker, Mahmoud

AU - Shahabi, Nahid A.

AU - Sharp, Burt

PY - 1994/1/1

Y1 - 1994/1/1

N2 - β-Endorphin affects mononuclear cell proliferation, cytokine production and calcium uptake in a naloxone-resistant manner. The presence of naloxone-insensitive binding sites for β-endorphin have been demonstrated on murine EL4-thymoma cells, transformed human mononuclear cells and normal murine splenocytes. Since murine splenic B cells have been shown to express naloxone-resistant receptors for β-endorphin in response to the mitogen, concanavalin A (Con A), the A20 B-cell lymphoma line was used to further study regulation of this site by Con A and dexamethasone. Analyses showed two sites: a high-affinity site, Kd1 = (8.7 ± 2.3) × 10-11 M and binding capacity (Bmax1 ) of (2.6 ± 2.0) × 103 receptors/cell; and a low-affinity site, Kd2 = (2.2 ± 0.8) × 10-8 M with Bmax2 of (1.5 ± 0.8) × 105 receptors/cell. Competition studies showed that N-acetyl-β-endorphin was approx. 5-fold and β-endorphin6-31 10-fold less potent than β-endorphin1-31. Neither β-endorphin1-27 nor naloxone, morphine or other opioid receptor agonists displaced [125I]β-endorphin. Con A (20 μg/ml) significantly increased the Bmax (3.5-fold; expressed per cell) and resulted in a loss of the higher-affinity site. However, the increased Bmax occurred in proportion to the Con-A-induced increase in protein/cell. Dexamethasone (Dex) also increased Bmax, primarily by increasing (2-3-fold) the number of lower affinity sites. In contrast to Con A, two binding sites persisted after treatment with Dex, which exerted a minimal effect on protein/cell. Therefore, binding/cell and binding/protein/cell were both significantly enhanced by Dex. The combined effects of Dex and Con A on binding failed to show additivity or synergy. When binding was analyzed per protein/cell, the effect of Con A appeared to dominate; the Dex-enhanced binding/protein/cell was no longer evident in the presence of Dex plus Con A. Thus, Dex and Con A may enhance binding by independent mechanisms.

AB - β-Endorphin affects mononuclear cell proliferation, cytokine production and calcium uptake in a naloxone-resistant manner. The presence of naloxone-insensitive binding sites for β-endorphin have been demonstrated on murine EL4-thymoma cells, transformed human mononuclear cells and normal murine splenocytes. Since murine splenic B cells have been shown to express naloxone-resistant receptors for β-endorphin in response to the mitogen, concanavalin A (Con A), the A20 B-cell lymphoma line was used to further study regulation of this site by Con A and dexamethasone. Analyses showed two sites: a high-affinity site, Kd1 = (8.7 ± 2.3) × 10-11 M and binding capacity (Bmax1 ) of (2.6 ± 2.0) × 103 receptors/cell; and a low-affinity site, Kd2 = (2.2 ± 0.8) × 10-8 M with Bmax2 of (1.5 ± 0.8) × 105 receptors/cell. Competition studies showed that N-acetyl-β-endorphin was approx. 5-fold and β-endorphin6-31 10-fold less potent than β-endorphin1-31. Neither β-endorphin1-27 nor naloxone, morphine or other opioid receptor agonists displaced [125I]β-endorphin. Con A (20 μg/ml) significantly increased the Bmax (3.5-fold; expressed per cell) and resulted in a loss of the higher-affinity site. However, the increased Bmax occurred in proportion to the Con-A-induced increase in protein/cell. Dexamethasone (Dex) also increased Bmax, primarily by increasing (2-3-fold) the number of lower affinity sites. In contrast to Con A, two binding sites persisted after treatment with Dex, which exerted a minimal effect on protein/cell. Therefore, binding/cell and binding/protein/cell were both significantly enhanced by Dex. The combined effects of Dex and Con A on binding failed to show additivity or synergy. When binding was analyzed per protein/cell, the effect of Con A appeared to dominate; the Dex-enhanced binding/protein/cell was no longer evident in the presence of Dex plus Con A. Thus, Dex and Con A may enhance binding by independent mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0028172163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028172163&partnerID=8YFLogxK

U2 - 10.1016/0162-3109(94)90053-1

DO - 10.1016/0162-3109(94)90053-1

M3 - Article

VL - 28

SP - 183

EP - 192

JO - Immunopharmacology

JF - Immunopharmacology

SN - 0162-3109

IS - 3

ER -